-+ 0.00%
-+ 0.00%
-+ 0.00%

Jefferies Maintains Buy on Hemab Therapeutics Hldgs, Raises Price Target to $47

Benzinga·07/13/2026 18:39:56
语音播报
Jefferies analyst Maury Raycroft maintains Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Buy and raises the price target from $39 to $47.